Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).  

The companies are working to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing. 

As the global burden of metabolic disease rises, liver health experts are sounding the alarm about the importance of identifying the disease before it advances to fibrosis, cirrhosis, or other serious complications. The collaboration between Siemens Healthineers and Novo seeks to advance solutions that make MASH assessment more accessible and actionable across the healthcare continuum. This includes broader awareness and adoption of noninvasive testing (NIT) approaches that can provide clinicians with valuable information about liver health while helping reduce reliance on invasive procedures. 

Among these approaches is a blood test from Siemens Healthineers. The Enhanced Liver Fibrosis (ELF) test is the first and only blood test authorized in the United States to help clinicians assess risk of disease progression in patients with advanced fibrosis due to MASH and support patient management decisions. The simple test is available through major national laboratory providers and covered by a Category 1 CPT code (81517). Blood-based testing supports high patient demand and avoids failure rates and unreliable results reported for other non-invasive methods. For example, the ELF test results are not impacted by body composition characteristics such as BMI. 

Visit Siemens Healthineers for more information